Most cited papers from iResearch Atlanta

iResearch Atlanta

What are the most cited papers from iResearch Atlanta?

The most cited paper from iResearch Atlanta is "Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT" (Kimball A. Johnson, Nancy Martin, Rossella Elena Nappi et al., 2023), with 202 citations. Next come "Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age" (147) and "Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study" (118).

Published FieldAccessCitations

Showing 11 of 11 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT Kimball A. Johnson, Nancy Martin, Rossella Elena Nappi et al. · The Journal of Clinical Endocrinology & Metabolism Open access	3 Feb 2023	202
2	Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age Evan J. Anderson et al. · New England Journal of Medicine Open access	19 Oct 2022	147
3	Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study Gerard Sanacora, Michael R. Johnson, Arif Khan et al. · Neuropsychopharmacology Open access	29 Sep 2016	118
4	Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2) Rossella Elena Nappi, Kimball A. Johnson, Petra Stute et al. · Menopause The Journal of The North American Menopause Society Open access	16 Apr 2024	18
5	Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study Paul P. Yeung, Kimball A. Johnson, Robert A. Riesenberg et al. · Journal of Child and Adolescent Psychopharmacology Open access	12 Jul 2023	10
6	INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease Eric Siemers, Todd Feaster, Gopalan Sethuraman et al. · The Journal of Prevention of Alzheimer s Disease Open access	2025	7
7	Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study Elena A. Christofides et al. · Diabetes Obesity and Metabolism	Apr 2024	5
8	1.40 Long-Term Safety of Cariprazine in Pediatric Patients With Schizophrenia, Bipolar I Disorder, or ASD: Interim Results From an Open-Label Study M. Lerma Lucas, Diab Almhana, Nelson M. Handal et al. · Journal of the American Academy of Child & Adolescent Psychiatry	Oct 2025	1
9	Fezolinetant for hot flashes associated with menopause: SKYLIGHT 1 and SKYLIGHT 2 Samuel Lederman, Kimball Johnson, Faith D. Ottery et al. · Video Journal of Biomedicine Open access	17 Dec 2025	0
10	Fezolinetant treatment for hot flashes associated with menopause: a plain language summary of the SKYLIGHT 1 and SKYLIGHT 2 studies Samuel N. Lederman, Kimball Johnson, Faith D. Ottery et al. · Future Endocrinology & Metabolism Open access	7 May 2025	0
11	Treatment of moderate-to-severe vasomotor symptoms associated with menopause with fezolinetant: pooled responder analysis from SKYLIGHT 1 and 2 Rossella Elena Nappi, Kimball Johnson, Petra Stute et al. · Maturitas	7 Jun 2023	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.